Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: Clin Immunol. 2009 May 26;132(3):401–411. doi: 10.1016/j.clim.2009.05.002

Figure 5. Suppressive response to HCV core in acute-to-resolved and acute-to-chronic individuals.

Figure 5

PBMC of acute-to-resolved and acute-to-chronic patients were stimulated with anti-CD3/CD28 antibodies for 5 days in the presence or absence of HCV core antigen or β-gal control protein. [3H]-thymidine was added to wells on the fifth day of culture and incubated for an additional 18 hours before cell harvest. A) Percent inhibition of proliferation of healthy donors and infected patients at time of enrollment (Month 0). Mann-Whitney analysis. P-value significance is p<0.05. B) Percent inhibition of proliferation of healthy donors and infected patients at Month 6. C) Percent inhibition of proliferation of healthy donors and long-term chronic patients. D) Matched pairs analysis of change in inhibition of proliferation from Month 0 to Month 6 in acute-to-resolved patients (n=7). Wilcoxon analysis. P-value significance is p<0.05. E) Matched pairs analysis of change in inhibition of proliferation from month 0 to month 6 in acute-to-chronic patients (n=9).